Search | Clinical Trials Finder

Conditions: Pregnancy Related, Influenza, Human
Interventions: There is no intervention.; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions: Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 146
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 123 more

Conditions: Breast Cancer
Interventions: conventional surgery, Sentinel node resection followed by node examination; Procedure
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 5,611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2014
U.S. locations: 68
States / cities: Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 61 more

Conditions: Sleep Apnea, Obstructive
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 60
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more

Conditions: Joint Infection
Interventions: PLG0206; Drug
Lead sponsor: Peptilogics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Palo Alto, California • Sarasota, Florida • Baltimore, Maryland + 8 more

Conditions: Solid Tumor
Interventions: Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 30 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 7
States / cities: Little Rock, Arkansas • Palo Alto, California • Boston, Massachusetts + 4 more

Conditions: Type 1 Diabetes
Interventions: Extended Wear Infusion Set, Standard Infusion Set; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Total Joint Replacement Surgery
Interventions: SPARTA force plate; Device
Lead sponsor: Derek Amanatullah; Other
Eligibility: 18 Years to 99 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Membranous Nephropathy
Interventions: Felzartamab, Tacrolimus, Standard of Care IST; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more

Conditions: Epilepsy
Interventions: Perampanel 1 week titration, Perampanel 2 week titration, Perampanel 4mg, Placebo; Drug
Lead sponsor: Kimford Jay Meador; Other
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York

Conditions: Huntingtons Disease
Interventions: RO7234292, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more

Conditions: Disorders of Gut-brain Interaction, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome, Abdominal Pain, Esophageal Disease
Interventions: Gut directed hypnotherapy via telephone intervention, Educational recording; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lazertinib, Amivantamab, Carboplatin, Pemetrexed; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 12 more

Conditions: Obstructive Sleep Apnea, Central Sleep Apnea (Diagnosis), Chronic Opioid Use
Interventions: Adaptive servo-ventilation (ASV), Bi-Level PAP; Device
Lead sponsor: ResMed; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Stage 0 Nasopharyngeal Carcinoma, Stage 0 Paranasal Sinus Cancer, Stage I Nasopharyngeal Carcinoma, Stage I Paranasal Sinus Cancer, Stage II Nasopharyngeal Carcinoma, Stage II Paranasal Sinus Cancer, Stage IIA Nasopharyngeal Carcinoma, Stage IIB Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage III Paranasal Sinus Cancer, Stage IV Nasopharyngeal Carcinoma, Stage IV Paranasal Sinus Cancer, Stage IVA Nasopharyngeal Carcinoma, Stage IVA Paranasal Sinus Cancer, Stage IVB Nasopharyngeal Carcinoma, Stage IVB Paranasal Sinus Cancer, Stage IVC Nasopharyngeal Carcinoma, Stage IVC Paranasal Sinus Cancer
Interventions: Physiologic Testing, Quality-of-Life Assessment, Sham Intervention, Therapeutic Procedure, rose essential oil, lemon essential oil, clove essential oil, eucalyptus essential oil, canola oil placebo; Other · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Adenovirus Disease
Interventions: Brincidofovir, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 3 Months to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: Hemorrhage
Interventions: Blood drainage post cardiac surgery; Device
Lead sponsor: Centese, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: AP System (DiAs or inControl) with USS Virginia, Sensor-Augmented Pump Therapy (placebo); Device
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Stanford, California • Charlottesville, Virginia

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more

Conditions: Pain, Chronic, Pain, Joint Pain, Musculoskeletal Pain
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 11 Years to 18 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Palo Alto, California • Cincinnati, Ohio

Conditions: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 321
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 244 more

Search by objective public record fields.

NK Cell Mediated Influenza Immunity During Pregnancy

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

A Rehabilitation Tool to Determine Patient's Stay in Hospital After Joint Replacement

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Perampanel Titration and Cognitive Effects

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use

H5 Adult - Chiron Study of Bird Flu Vaccine

Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

Experiences With Automated Surgical Drainage in Cardiac Surgery

USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

SPRINT: Signature for Pain Recovery IN Teens

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer